BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18585507)

  • 1. Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis.
    Ko DT; Chiu M; Austin PC; Bowen J; Cohen EA; Tu JV
    Am Heart J; 2008 Jul; 156(1):125-34. PubMed ID: 18585507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.
    Ko DT; Chiu M; Guo H; Austin PC; Goeree R; Cohen E; Labinaz M; Tu JV
    J Am Coll Cardiol; 2009 May; 53(19):1773-82. PubMed ID: 19422984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.
    Kim YH; Park DW; Lee SW; Yun SC; Lee CW; Hong MK; Park SW; Seung KB; Gwon HC; Jeong MH; Jang Y; Kim HS; Seong IW; Park HS; Ahn T; Chae IH; Tahk SJ; Chung WS; Park SJ;
    Circulation; 2009 Aug; 120(5):400-7. PubMed ID: 19620506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-eluting compared with bare-metal coronary stents among elderly patients.
    Groeneveld PW; Matta MA; Greenhut AP; Yang F
    J Am Coll Cardiol; 2008 May; 51(21):2017-24. PubMed ID: 18498954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of drug-eluting stents in Ontario.
    Tu JV; Bowen J; Chiu M; Ko DT; Austin PC; He Y; Hopkins R; Tarride JE; Blackhouse G; Lazzam C; Cohen EA; Goeree R
    N Engl J Med; 2007 Oct; 357(14):1393-402. PubMed ID: 17914040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry.
    Dou KF; Xu B; Yang YJ; Chen JL; Qiao SB; Li JJ; Qin XW; Liu HB; Wu YJ; Chen J; Yao M; You SJ; Yuan JQ; Dai J; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):612-6. PubMed ID: 19323921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.
    Ortolani P; Balducelli M; Marzaroli P; Piovaccari G; Menozzi A; Guiducci V; Sangiorgio P; Tarantino F; Geraci G; Castriota F; Tondi S; Saia F; Cooke RM; Guastaroba P; Grilli R; Marzocchi A; Maresta A
    Circulation; 2008 Feb; 117(7):923-30. PubMed ID: 18250265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-eluting versus bare-metal stents in acute ST elevation myocardial infarction (STEMI).
    Hamirani YS; Jibrin I; Abraham D; Merriman B; Wenz C; Bahr RD
    Crit Pathw Cardiol; 2008 Dec; 7(4):232-8. PubMed ID: 19050419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry.
    Abbott JD; Voss MR; Nakamura M; Cohen HA; Selzer F; Kip KE; Vlachos HA; Wilensky RL; Williams DO
    J Am Coll Cardiol; 2007 Nov; 50(21):2029-36. PubMed ID: 18021868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Roy P; Buch AN; Javaid A; Okabe T; Raya V; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Gevorkian N; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Feb; 101(3):293-9. PubMed ID: 18237587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
    Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
    Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions.
    Han YL; Zhang J; Li Y; Wang SL; Jing QM; Yi XH; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2009 Mar; 122(6):643-7. PubMed ID: 19323927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
    Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
    Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term results of unprotected left main percutaneous coronary intervention with DES versus BMS.
    Capodanno D; Di Salvo ME; Capranzano P; Seminara D; Caggegi A; Barrano G; Tamburino C
    Minerva Cardioangiol; 2009 Feb; 57(1):1-6. PubMed ID: 19202514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentations and outcomes.
    Hayes KR; Applegate RJ; Sacrinty MT; Kutcher MA; Gandhi SK; Santos RM; Little WC
    J Invasive Cardiol; 2010 Jun; 22(6):266-70. PubMed ID: 20516505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year clinical outcomes following elective drug-eluting versus bare-metal stent implantation: results from a large single-center database.
    Gao RL; Xu B; Chen JL; Yang YJ; Qiao SB; Wang Y; Dou KF; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li W
    Chin Med J (Engl); 2009 Oct; 122(19):2261-7. PubMed ID: 20079124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.